UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

OF THE SECURITIES EXCHANGE ACT OF 1934

April 12 19, 2024

(Commission File No. 001-38475)

ASLAN PHARMACEUTICALS LIMITED

(REG. NO. 289175)

(Translation of registrant’s name into English)

CAYMAN ISLANDS

(Jurisdiction of incorporation or ~~organisation~~organization)

3 Temasek Avenue

Level 18 Centennial Tower

Singapore 039190

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F  ☒ Form 40-F  ☐

~~First~~Announcement ~~Quarter~~of ~~2024~~Receipt ~~Cash~~of ~~Update~~Nasdaq Deficiency Notice Regarding Minimum Equity Requirement

On April 18, 2024 ASLAN Pharmaceuticals Limited (the “Company”) ~~estimates~~received ~~that~~a ~~its~~letter ~~cash~~(the ~~and~~“Letter”) ~~cash~~from ~~equivalents~~The ~~were~~Nasdaq ~~approximately~~Stock ~~$18.4~~Market (“Nasdaq”) ~~million~~informing asthe ofCompany ~~March~~that ~~31,~~it ~~2024.~~failed ~~This amount is preliminary, has not been reviewed and is subject~~ to ~~change~~maintain ~~upon completion of~~ the ~~Company’s~~continued ~~consolidated~~listing ~~financial~~requirement ~~statements~~under asNasdaq ofListing ~~and~~Rule 5550(b)(1) for the ~~three~~Nasdaq ~~months~~Capital ~~ended~~Market, ~~March~~which ~~31,~~requires ~~2024.~~that ~~The~~a ~~Company~~listed company’s ~~independent~~stockholders’ ~~registered~~equity ~~public~~be ~~accounting~~at least ~~firm has not audited, reviewed or performed any procedures with respect to these preliminary results and, accordingly, does not express an opinion or any other form of assurance about them~~$2.5 ~~Additional~~million ~~information~~(the ~~and~~“Stockholders’ ~~disclosures~~Equity ~~would be required for a more complete understanding of our liquidity, financial position and results of operations as of March 31, 2024~~Requirement”).

~~ATM~~Based ~~Sale~~upon ~~Agreement~~the reported stockholders’ equity of a deficit of $13.3 million in the Company’s Form 20-F for the period ended December 31, 2023, the Company did not meet the Stockholders’ Equity Requirement.

AsThe ~~previously disclosed in the Form 6-K filed with the Securities and Exchange Commission (“SEC”) on October 9, 2020, the~~ Company ~~entered~~has ~~into~~a anperiod ~~Open~~of ~~Market~~45 ~~Sale~~calendar ~~AgreementSM~~days onfrom ~~October 9, 2020, as subsequently amended on September 13, 2022 (~~the ~~“Sale~~date ~~Agreement”) with Jefferies LLC to issue and sell American Depositary Shares~~ of the ~~Company (“ADSs”)~~Letter, ~~with~~or ~~each~~until ~~ADS~~June 3, ~~representing~~2024, ~~twenty-five~~to ~~ordinary~~submit ~~shares~~a ofplan ~~the Company, from time~~ to ~~time,~~regain ~~through~~compliance anwith ~~at-~~the~~-market~~ Stockholders’ ~~offering~~Equity ~~under~~Requirement ~~which Jefferies LLC will act as sales agent and/or principal~~ (the “~~Agent~~Compliance Plan”).

OnThe ~~April~~Letter ~~12,~~has ~~2024,~~no ~~the~~immediate ~~Company~~effect ~~filed~~on athe ~~prospectus~~listing ~~supplement~~or ~~relating~~trading toof the Company’s ~~sale~~American ofDepositary ~~the~~Shares ~~ADSs~~representing ~~(the~~ordinary ~~“Prospectus~~shares ~~Supplement~~(“ADSs”), ~~pursuant to~~ which ~~the~~will ~~Company~~continue ~~may~~to ~~offer~~be ~~and~~listed ~~sell~~on ~~ADSs~~Nasdaq ~~having~~during anthis ~~aggregate offering price of up to $12~~period,~~000,000~~ ~~from~~subject ~~time~~ to ~~time through~~ the ~~Agent. The Prospectus Supplement was filed under the~~ Company’s ~~shelf~~compliance ~~registration~~with ~~statement~~other onlisting ~~Form F-3 (Registration No. 333-270835) (the “Registration Statement”)~~standards, ~~which~~under ~~was initially filed with~~ the ~~Securities and Exchange Commission on March 24, 2023, and which became effective on April 6, 2023~~symbol ‘ASLN’.

OnThe ~~April~~Company ~~12,~~announced ~~2024,~~ the ~~Company~~receipt ~~and~~of the ~~Agent~~Letter ~~entered~~through ~~into~~ a ~~second~~press ~~amendment~~release toon ~~the~~April 19, ~~Sale~~2024 ~~Agreement~~ (the “~~Second~~Press ~~Amendment~~Release”) to, ~~among~~which is ~~other~~attached ~~things,~~hereto ~~reference~~as ~~the Registration Statement~~Exhibit 99.1.

AThe ~~copy~~Company ofcurrently ~~the~~anticipates ~~Second~~timely ~~Amendment~~submitting isthe ~~attached~~Compliance ~~hereto~~Plan asto ~~Exhibit 99~~Nasdaq.1 ~~and~~If the Compliance Plan is submitted ~~incorporated~~and ~~herein~~accepted, byNasdaq ~~reference.~~may ~~The~~grant ~~foregoing~~an ~~description~~extension of up to 180 calendar days from the ~~Second~~date ~~Amendment~~of ~~does~~the ~~not~~Letter ~~purport~~for the Company to beregain ~~complete~~compliance. ~~and~~If the Compliance Plan is ~~qualified~~not inaccepted ~~its~~or ~~entirety~~the byCompany ~~reference~~is not granted an extension, the Company will then consider actions appropriate to ~~such~~the ~~exhibit~~circumstances, which may include applicable appeals to a Nasdaq Hearings Panel.

AThere ~~copy~~can ofbe no assurance, however, that the ~~opinion~~Company ofwill ~~Walkers~~be ~~(Singapore)~~able ~~Limited~~to ~~Liability~~regain ~~Partnership~~compliance ~~relating~~with the Stockholders’ Equity Requirement, and even if it does, there can be no assurance that the Company will be able to maintain compliance with the ~~validity~~continued oflisting requirements for the ~~securities~~Nasdaq toCapital Market or that the Company’s ADSs will not be ~~issued~~delisted in ~~accordance~~the ~~with~~future. In addition, the ~~Sale~~Company ~~Agreement~~may isbe ~~filed~~unable ~~herewith~~to asmeet ~~Exhibit~~other 5applicable listing requirements of the Nasdaq Capital Market, including maintaining the minimum bid price requirement or market values of the Company’s ADSs, in which case, the ADSs could be delisted notwithstanding the Company’s ability to demonstrate compliance with the Stockholders’ Equity Requirement.1.

~~The~~Delisting ~~information~~from ~~contained~~the inNasdaq ~~this~~Capital ~~Form~~Market ~~6-K,~~may ~~including~~adversely ~~Exhibit~~affect ~~5.1, is hereby incorporated by reference into~~ the Company’s ~~Registration~~ability ~~Statement~~to onraise ~~Form~~additional ~~F-3~~financing ~~(File~~through ~~No.~~the ~~333-254768),~~public ~~Registration~~or ~~Statement~~private onsale ~~Form~~of equity ~~F-3 (File No. 333-270835)~~securities, ~~Registration~~may ~~Statement~~significantly onaffect ~~Form~~the ~~F-3~~ability ~~(File~~of ~~No.~~investors ~~333-270837),~~to ~~Registration~~trade ~~Statement~~the onCompany’s ~~Form~~securities ~~F-3~~and ~~(File~~may ~~No.~~negatively ~~333-278217),~~affect ~~Registration~~the ~~Statement~~value onand ~~Form~~liquidity ~~S-8~~of ~~(File~~the NoCompany’s ADSs. ~~333-252118),~~Delisting ~~Registration~~also ~~Statement~~could onhave ~~Form~~other ~~S-8~~negative ~~(File No. 333-263843)~~results, ~~Registration~~including ~~Statement~~the potential onloss ~~Form~~of ~~S-8~~employee ~~(File~~confidence, ~~No.~~the ~~333-270832)~~loss ~~and~~of ~~Registration~~institutional ~~Statement~~investors onor ~~Form~~interest ~~S-8~~in ~~(File~~business ~~No.~~development ~~333-278634)~~opportunities.

The information contained in this Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (File No. 333-254768), Registration Statement on Form F-3 (File No. 333-270835), Registration Statement on Form F-3 (File No. 333-270837), Registration Statement on Form F-3 (File No. 333-278217), Registration Statement on Form S-8 (File No. 333-252118), Registration Statement on Form S-8 (File No. 333-263843), Registration Statement on Form S-8 (File No. 333-270832) and Registration Statement on Form S-8 (File No. 333-278634).

Forward Looking Statements

This Form 6-K contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of the Company. These forward-looking statements may include, but are not limited to, statements regarding the Company’s ~~preliminary~~plan ~~estimates~~to ofsubmit ~~cash~~the Compliance Plan to Nasdaq and ~~cash~~the ~~equivalents~~Company’s asability ofto ~~March~~regain ~~31,~~compliance ~~2024~~with the Stockholders’ Equity Requirement and continue to be listed on Nasdaq. The Company’s estimates, projections and other forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and inherently involve significant known and unknown risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of ~~these~~many risks and uncertainties., ~~Such~~which include, unexpected safety or efficacy data observed during preclinical or clinical studies; risks ~~and~~that ~~uncertainties~~future ~~include,~~clinical ~~but~~trial ~~are~~results may not ~~limited~~be toconsistent with interim, initial ~~the~~or ~~risk~~preliminary ~~that~~results ~~actual~~or ~~cash~~results ~~and~~from ~~cash~~prior ~~equivalents,~~preclinical studies or clinical trials; risks that trends or characteristics based on preliminary blinded data may not be consistent with unblinded data; clinical site activation rates or clinical trial enrollment rates that are lower than expected; the ~~completion~~impact of ~~financial~~health ~~closing~~epidemics ~~procedures~~or pandemics, or geopolitical conflicts on the Company’s operations, research and development and clinical trials and potential disruption in the operations and business of ~~complete~~third-party ~~first~~manufacturers, ~~quarter~~contract ~~2024~~research ~~results~~organizations, ~~may~~other ~~vary~~service ~~from~~providers ~~projections~~and collaborators with whom the Company conducts business; general market conditions; changes in the competitive landscape; and the Company’s ability to obtain sufficient financing to fund its strategic and clinical development plans. Other factors that may cause actual results to differ from those expressed or implied in such forward-looking statements are described in the Company’s SEC filings and reports (Commission File No. 001-38475), including the Company’s Form 20-F filed with the SEC on April 12, 2024. All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.

Exhibits

ExhibitNumber		Exhibit Description
5.1		Opinion of Walkers (Singapore) Limited Liability Partnership, Cayman Islands counsel to the Company.
99.1		Press release dated April 19, 2024
23.1		Consent of Walkers (Singapore) Limited Liability Partnership (included in Exhibit 5.1).
99.1		Amendment No. 2 to the Open Market Sale AgreementSM, dated as of April 12, 2024, by and between the Company and Jefferies LLC.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto ~~hereto~~ duly authorized.


ASLAN PHARMACEUTICALS LIMITED
(Registrant)

By:		/s/ Kiran Kumar Asarpota
Name:		Kiran Kumar Asarpota
Title:		Chief Operating Officer

Date: April 12 19, 2024

Filing Compare · ASLAN Pharmaceuticals Ltd